

DNA sequence of the 5' flanking region of the human interleukin 2 gene: homologies with adult T-cell leukemia virus

Nikki J.Holbrook, Michael Lieber and Gerald R.Crabtree

Laboratory of Pathology, National Cancer Institute, Building 10, Room 2N-113, Bethesda,
MD 20205, USA

Received 14 May 1984; Accepted 23 May 1984

ABSTRACT

We previously reported the sequence of the gene for human interleukin 2 (IL-2) which included about 220 b.p. of the 5' flanking region. In this report we have extended the 5' sequence to 1263 b.p. before the start site of transcription and have compared the entire sequence of the IL-2 gene and its 5' flanking region with that of Adult T-cell leukemia virus (ATLV). Four regions of limited homology were noted. Three areas of homology to the viral long terminal repeat (LTR) were seen in the 5' sequence flanking IL-2. A fourth region of homology to the viral LTR was located within the second intron of the IL-2 gene. While the significance of these homologies is not known, it is possible that they are involved in regulating the expression of ATLV and IL-2, both of which are generally restricted to T cells.

INTRODUCTION

Interleukin 2 (IL-2), also known as T-cell growth factor (TCGF), is a lymphokine produced by lectin- or antigen-stimulated T cells which is capable of initiating and maintaining long term *in vitro* growth of activated T cells (1). Although the protein has been purified to homogeneity (2,3) and its biological effects studied extensively (2-5), little is known about its regulation at a genetic level. In addition to antigen, mitogens such as phytohemagglutinin and concanavalin A induce IL-2 production in human T lymphocytes (2,6). The tumor promoter phorbol myristic acetate, by itself does not induce IL-2 production, but enhances the induction by mitogen or antigen (2,6). Recently, a monoclonal antibody to a cell surface protein on T cells (T3) was shown to induce IL-2 mRNA (7). This latter effect is probably mediated by the same mechanism which antigens use to activate cell division, since T3 appears to be part of the T cell antigen receptor complex. Thus it is likely that the activation of the IL-2 gene will serve as a useful model for studying the way in which antigens initiate the orderly and sequential activation of genes that lead to clonal expansion of T lymphocytes.

To study the processes involved in regulation of IL-2 at the molecular level we cloned the gene from a human DNA library. Recently, we (8) and



Figure 1. Restriction map and sequencing strategy for the 5' flanking region of the human IL-2 gene. Rectangles indicate the exons of the gene. Arrows indicate the direction and extent of sequence analysis of individual fragments. The sequence is represented 5' to 3' from left to right. E, EcoR I; H, Hind III; X, Xba I; A, Alu I; R, Rsa I. The dotted arrow indicates the overlapping 5' end of our previously published sequence.

Fugita et al. (9) independently reported the structure and complete nucleotide sequence of the IL-2 gene. The gene, which is comprised of four exons separated by intervening sequences, occurs as a single copy in the genome. Few discrepancies occur in the two reported sequences. Most of these involve single base-pair substitutions or deletions in the third intron of the gene. At present, the published nucleic acid sequence for the 5' flanking region of the IL-2 gene extends about 430 b.p. upstream from the site for initiation of transcription (9). In view of the potential role of DNA sequences farther 5' influencing expression of IL-2 we sequenced an additional 900 b.p. of the 5' flanking region. Comparision of the sequence of IL-2 with the sequence for Adult T-cell leukemia virus (ATLV) (10,11) revealed several areas of homology within the 5' end of IL-2 and the long terminal repeat (LTR) of ATLV.

MATERIALS AND METHODS

Materials. DNA polymerase was from Boehringer Mannheim; restriction endonucleases were from New England BioLabs; T4 DNA ligase, M13 phage vectors and unlabeled deoxynucleotide triphosphates and dideoxynucleotide triphosphates were from P-L Biochemicals; and [32 P]deoxynucleotide triphosphates were from Amersham.

DNA sequencing and analysis. The DNA sequences were determined by the chain termination method of Sanger et al. (12) as described previously (8). Sequences were analyzed and compared on an IBM system 370 computer using a program described by Queen and Korn (13) and were analyzed graphically by standard dot matrix plots (14).

AGTGGTTTT 60
 GGAGTCAGTA CATTCTCTT TCAAATCCTT CTCTGCCCT TACTGGCAAT
 AAGGGCTGAG 120
 TGACCTAGAG GCAAATTACT TAACTTCTCT GAGCCTCAGT TTTCTAATCT
 GCAAATAGG 180
 AGCCATCACT TCACAAGTCT GTAAGACTTA TATTAGACTA AGTGCCTGCC
 TGACACTGT 240
 TCTCTTTTC TCTCTTCTA TATACTGAA GGCATTATAG TGCTAGATGT
 CTGTTAAAG 300
 ACCAGACAAT ATTGTCTAA AAAAACAAAC AAAAACACAG ACAATACCAT
 CTTAAAAAA 360
 AAAAAGAG TCCAGGTAAG AAATAAATAA GGCCATAGAA TGGAAGCTT
 ACAAGGACTC 420
 TCTTGAGAC AGGATCTCT CAAGTGTCCC CAGGTTAAAT TAGAAGTATA
 TATCCGTACA 480
 ATTGTTGAG CAGTTGTC ACTGTACTGA GGATGAATGA ACACCTATCC
 TAAATATCCT 540
 AGTCTTCTGA CTAACACAA GATCATATT CATAACGATT ATTGTTACAT
 TCATAGTGTC 600
 CCAGGTGATT TAGAGGATAA ATAAAATCC ATAAAAGAGG TAAAGACATA
 AAAACGAGAA 660
 ACATGGACTG GTTACACAT AACACATACA AAGTCTATTA TAAAACACTAGC
 ATCAGTATCC 720
 TTGAATCGAA ACCTTTTCT GAGTATTTAA CAATCGCACC CTTAAAAAAA
 TGACATAGA 780
 CATTAAGAGA CTTAACAGA TATATAATCA TTTAAATTAA AAATAGCGTT
 AAACAGTACC 840
 TCAAGCTCAA TAAGCATTTT AAGTATTCTA ATCTTAGTAT TTCTCTAGCT
 GACATGTAAG 900
 AAGCAATCTA TCTTATTGTA TGCAATTAGC TCATTGTGTG GATAAAAAGG
 TAAAACCATT 960
 CTGAAACAGG AAACCAATAC ACTTCCTGTT TAATCAACAA ATCTAAACAT
 TTATTCTTT 1020
 CATCTGTTA CTCTGCTCT TGTCACCCAC AATATGCTAT TCACATGTT
 AGTGTAGTT 1080
 TATGACAAAG AAAATTTCT GAGTTACTTT TGTATCCCCA CCCCCCTTAA
 GAAAGGAGGA 1140
 AAAACTGTTT CATAACAGAAG GCGTTAATTG CATGAATTAG AGCTATCAC
 TAAGTGTGGG 1200
 CTAATGTAAC AAAGAGGGAT TTCACCTACA TCCATTCAAGT CAGTCTTGG
 GGGTTAAAG 1260
 AAATTCCAAA GAGTCATCAG AAGAGGAAAA ATGAAGGTAA TGTTTTTCA
 GACTGGTAA 1320
 GTCTTGAAA ATATGTGTA TATGTAAAAC ATTTGACAC CCCCATATAA
 TTTTCCAGA 1380
 ATTAACAGTA TAAATTGCACT CTCTGTTCA AGAGTCCCT ATCACTCTT
 1433

AATCACTACT CACAGTAACC TCAACTCCTG CCACA ATG TAC AGG ATG CAA CTC
 Met Tyr Arg Met Gln Leu

1490
 CTG TCT TGC ATT GCA CTA AGT CTT GCA CTT GTC ACA AAC AGT GCA CCT ACT TCA AGT
 Leu Ser Cys Ile Ala Leu Ser Leu Ala Leu Val Thr Asn Ser Ala Pro Thr Ser Ser

Figure 2.

1547

TCT ACA AAG AAA ACA CAG CTA CAA CTG GAG CAT TTA CTG CTG GAT TTA CAG ATG ATT
Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile

1602

TTG AAT GGA ATT AAT GTAAGTATAT TTCCCTTCTT ACTAAAATTA TTACATTTAG
Leu Asn Gly Ile Asn

1661

TAATCTAGCT GGAGATCATT TCTTAATAAC AATGCATTAT ACTTTCTTAG AAT TAC AAG
Asn Tyr Lys

1712

AAT CCC AAA CTC ACC AGG ATG CTC ACA TTT AAG TTT TAC ATG CCC AAG AAG
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys

1772

GTAAGTACAA TATTTATGT TCAATTCTG TTTTAATAAA ATTCAAAGTA ATATGAAAAT

1832

TTGCACAGAT GGGACTAATA GCAGCTCATC TGAGGTAAAG AGTAACCTTA ATTTGTTTT

1892

TTGAAAACCC AAGTTTGATA ATGAAGCCTC TATTAACACA GTTTACCTA TATTTTAAAT

1952

ATATATTTGT GTGTTGGTGG GGGTGGGAGA AAACATAAAA ATAATATTCT CTCACTTTAT

2012

CGATAAGACA ATTCTAAACA AAAATGTTCA TTTATGGTTT CATTAAAAAA TGAAAACCTC

2072

TAAAATATTT GATTATGTCA TTTAGTATG TAAAATACCA AAATCTATTT CCAAGGAGCC

2132

CACTTTAAA AATCTTTCT TGTTTAGGA AAGGTTCTA AGTGAGAGGC AGCATAACAC

2192

TAATAGCACA GAGTCTGGGG CCAGATATCT GAAGTGAAAT CTCAGCTCTG CCATGTCCTA

2252

GCTTCATGA TCTTGGCAA ATTACCTACT CTGTTGTGA TTCAGTTCA TGTCTACTTA

2312

AATGAATAAC TGTTATACT TAATATGGCT TTGTGAGAAT TAGTAAGTAA ATGTTAAAGCA

2372

CTCAGAACCG TGTCTGGCAT AAGGTAAATA CCATACAAGC ATTAGCTATT ATTAGTAGTA

2432

TTAAAGATAA AATTTCACT GAGAAATACA AAGTAAAATT TTGGACTTTA TCTTTTACCC

2492

AATAGAACCT GAGATTTATA ATGCTATATG ACTTATTTTC CAAGATTTAA AGCTTCATTA

2552

GGTTGTTTT GGATTCAGAT AGAGCATAAG CATAATCATC CAAGCTCCTA GGCTACATTA

2612

GGTGTGTAAG GCTACCTAGT AGCTGTGCCA GTTAAGAGAG AATGAACAAA ATCTGGTGCC

2672

AGAAAGAGCT TGTGCCAGGG TGAATCCAAG CCCAGAAAATT AATAGGATTAA AAGGGGACAC

2732

AGATGCAATC CCATTGACTC AAATTCTATT AATTCAAGAC AAATCTGCTT CTAACTACCC

2792

TTCTGAAAGA TGAAAGGAG ACAGCTTACA GATGTTACTC TAGTTAATC AGAGCCACAT

2852

AATGCAACTC CAGCAACATA AAGATACTAG ATGCTGTGTTT CTGAAGAAAA TTTCTCCACA

2912

TTGTTCATGC CAAAAACTTA AACCCGAATT TGTAGAATTT GTAGTGGTGA ATTGAAAGCG

2972

CAATAGATGG ACATATCAGG GGATGGTAT TGTCTTGACC TACCTTCCC ACTAAAGAGT

3032

GTTAGAAAGA TGAGATTATG TGCTAAATT AGGGGTGGTA GAATTCAATGG AAATCTAAGT

TTGAAACCAA AAGTAATGAT AAACTCTATT CATTGTTCA TTTAACCCCTC ATTGCACATT 3092
 TACAAAAGAT TTTAGAAACT AATAAAAATA TTTGATTCCA AGGATGCTAT GTTAATGCTA 3152
 TAATGAGAAA GAAATGAAT CTAATTCTGG CTCTACCTAC TTATGTGGTC AAATTCTGAG 3212
 ATTTAGTGTG CTTATTTATA AAGTGGAGAT GATACTTCAC TGCTACTTC AAAAGATGAC 3272
 TGTGAGAAGT AAATGGGCCT ATTTGGAGA AAATTCTTT AAATTGTAAT ATACCATAGA 3332
 AATATGAAAT ATTATATATA ATATAGAAC AAGAGGCCG TCCAAAAGTC CTCCCAAAGT 3392
 ATTATAATCT TTTATTCAC TGGGACAAAC ATTTTAAAA TGCACTTAA TGTAGTGATT 3452
 GTAGAAAAGT AAAAATTAA GACATATTTA AAAATGTGTC TTGCTCAAGG CTATATTGAG 3512
 AGCCACTACT ACATGATTAT TGTTACCTAG TGAAAATGT TGGGATTGTG ATAGATGGCA 3572
 TCCAAGAGTT CCTCTCTCT CAACATTCTG TGATTCTAA CTCTTAGACT ATCAAATATT 3632
 ATAATCATAG AATGTGATT TTATGCCTTC CACATTCTAA TCTCATCTGG TTCTAATGAT 3692
 TTCTATGCA GATGGAAA GTAATCAGCC TACATCTGTA ATAGGCATT AGATGCAGAA 3752
 AGTCTAACAT TTTGCAAAGC CAAATTAAGC TAAAACAGT GAGTCAACTA TCACTAACG 3812
 CTAGTCATAG GTACTTGAGC CCTAGTTTT CCAGTTTAT AATGTAACACT CTACTGGCC 3872
 ATCTTACAG TGACATTGAG AACAGAGAGA ATGGTAAAAA CTACATACTG CTACTCCAA 3932
 TAAAATAAT TGGAAATTAA TTCTGATT TGACCTCTAT GTAAACTGAG CTGATGATAA 3992
 TTATTATTCT AG GCC ACA GAA CTG AAA CAT CTT CAG TGT CTA GAA GAA GAA CTC AAA 4049
 Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Leu Lys
 Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg 4106
 GAC TTA ATC AGC AAT ATC AAC GTA ATA GTT CTG GAA CTA AAG GTAAGGCATT 4158
 Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys
 ACTTTATTTG CTCTCCTGG AATAAAAAAA AAAAAGTAGG GGGAAAAGTA CCACATTTA 4218
 AAGTGACATA ACATTTTGG TATTTGTAAT GTACCCATGC ATGTAATTAG CCTACATTT 4278
 AAGTACACTG TGAACATGAA TCATTTCTAA TGTTAAATGA TTAACTGGGG AGTATAAGCT 4338
 ACTGAGTTG CACCTACCAT CTACTAATGG ACAAGCCTCA TCCCAAACTC CATCACCTT 4398
 CATATTAACA CAAAACGGG AGTGAGAGAG AAGTGAATGA GTTGAGTTTC ACAGAAACGC 4458
 AGGCAAGATT TTATTATATA TTTTCAAGT TCCTTCACAG ATCATTACT GGAATAGCCA 4518
 ATACTGAGTT ACCTGAAAGG CTTTCAAAAT GGTGTTCCCT TATCATTGTA TGGAAGGACT 4578
 ACCCATAAGA GATTTGTCTT AAAAAAAAAA ACTGGAGCCA TTAAAATGGC CAGTGGACTA 4638

4698

AACAAACAAC AATCTTTTA GAGGCAATCC CACTTCAGA ATCTTAAGTA TTTTTAAATG
 4758
 CACAGGAAGC ATAAAATATG CAAGGGACTC AGGTGATGTA AAAGAGATTG ACTTTTGCT
 4818
 TTTTATATCC CGTCTCCTAA GGTATAAAAT TCATGAGTTA ATAGGTATCC TAAATAAGCA
 4878
 GCATAAGTAT AGTAGTAAAA GACATTCCTA AAAGTAACTC CAGTTGTGTC CAAATGAATC
 4938
 ACTTATTAGT GGACTGTTTC AGTTGAATTA AAAAATACA TTGAGATCAA TGTCATCTAG
 4998
 ACATTGACAG ATTCACTTCC TTATCTATGG CAAGAGTTT ACTCTAAAAT AATTAAACATC
 5058
 AGAAAACCTCA TTCTTAACCTC TTGATACAAA TTTAAGACAA AACCATGCAA AAATCTGAAA
 5118
 ACTGTGTTTC AAAAGCCAAA CACTTTTAA AATAAAAAAA TCCAAGATA TGACAATATT
 5178
 TAAACAACTTA TGCTTAAGAG GATACAGAAC ACTGCAACAG TTTTTAAAAA GAGAATACCT
 5238
 ATTTAAAGGG AACACTCTAT CTCACCTGCT TTTGTTCCCA GGGTAGGAAT CACTTCAAT
 5298
 TTGAAAAGCT CTCTTTAAA TCTCACTATA TATCAAAATA GTTGCCTCCT TAGCTTATCA
 5358
 ACTAGAGGAA GCGTTAAAT AGCTCCTTC AGCAGAGAAG CCTAATTCTC AAAAAGCCAG
 5418
 TCCACAGAAC AAAATTCTA ATGTTTAAAG CTTTAAAG TTGGCAAATT CACCTGCATT
 5478
 GATACTATGA TGGGGTAGGG ATAGGTGTA GTATTTATGA AGATGTTCAT TCACACAAAT
 5538
 TTACCCAAAC AGGAAGCATG TCCTACCTAG CTTACTCTAG TGTAGCTCGT TTCGTCCTTG
 5598
 GGGAAAATAT AAGGAGATTG ACTTAAGTAG AAAAATAGGA GACTCTAATC AAGATTTAGA
 5658
 AAAGAAGAAA GTATAATGTG CATATCAATT CATACTTTA ACTTACACAA ATATAGGTGT
 5718
 ACATTAGAG GAAAAGCGAT CAAGTTTATT TCACATCCAG CATTAAATAT TTGTCAGAT
 5778
 CTATTTTAT TAAATCTT ATTTGCACCC AATTAGGGA AAAAATTTT GTGTTCATTG
 5838
 ACTGAATTAA CAAATGAGGA AAATCTCAGC TTCTGTGTTA CTATCATTG GTATCATAAC
 5898
 AAAATACGCA ATTTGGCAT TCATTTGAT CATTCAAGA AAATGTGAAT AATTAATATG
 5958
 TTTGGTAAGC TTGAAAATAA AGGCAACAGG CCTATAAGAC TTCAATTGGG AATAACTGTA
 6015
 TATAAGGTAA ACTACTCTGT ACTTTAAAAA ATTAACATT TTCTTTATA G GGA TCT
 Gly Ser
 6072
 GAA ACA ACA TTC ATG TGT GAA TAT GCT GAT GAG ACA GCA ACC ATT GTA GAA TTT CTG
 Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu
 6127
 AAC AGA TGG ATT ACC TTT TGT CAA AGC ATC ATC TCA ACA CTG ACT
 Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile Ile Ser Thr Leu Thr
 6187
TGCTTCCCA CTTAAACAT ATCAGGCCCT CTATTTATT AAATATTTAA ATTTATATT

TATTGTTGAA	TGTATGGTTT	GCTACCTATT	GTAACTATTA	TTCTTAATCT	TAAAACCTATA	6247
AATATGGATC	TTTATGATT	CTTTTGAA	GCCCTAGGGG	CTCTAAAATG	GTTCACCTTA	6307
TTTATCCCAA	AATATTTATT	ATTATGTTGA	ATGTTAAATA	TAGTATCTAT	GTAGATTGGT	6367
TAGTAAAAC	ATTTAATAAA	TTTGATAAAAT	ATAAACAAAGC	CTGGATATT	GTTATTTGG	6427
AAACAGCACA	GAGTAAGCAT	TTAAATATT	CTTAGTTACT	TGTGTGAAC	GTAGGATGGT	6487
TAAAATGCTT	ACAAAAGCTA	CTCTTCTCT	GAAGAAATAT	GTAGAACAGA	GATGTAGACT	6547
TCTCAAAAGC	CCTTGCTT	TCCTTCAAG	GGCTGATCAG	ACCCTTAGTT	CTGGCATCTC	6607
TTAGCAGATT	ATATTTCC	TCTTCTTAAA	ATGCCAAACA	CAAACACTCT	TGAAACTCTT	6667
CATAGATTG						GTTGGC

Figure 2. Complete DNA sequence of the human IL-2 gene and its 5' flanking region. The amino acid sequences encoded by exons of IL-2 are shown below the DNA sequences. The 3' and 5' untranslated regions are underlined. The TATA box, putative transcription initiation site, translation initiation site, termination codon and polyadenylation signal are enclosed in rectangles.

RESULTS AND DISCUSSION

The strategy for sequencing the 5' region flanking the IL-2 gene is shown in Fig. 1. The sequence obtained is shown in Fig. 2. Nucleotides 1-1133 represent newly determined sequence. For clarity and completeness we have also included our previously published sequence of the IL-2 gene.

Like the 3' untranslated region of IL-2, the 5' flanking DNA is highly rich in A residues. In particular, the segment extending from nucleotides 268-340 is comprised of 67% A residues with a long stretch of 14 A's and shares considerable homology with Alu family sequences (15).

Expression of Adult T-cell leukemia virus (ATLV), like that of IL-2 is highly specific for T cells. Using the computer program of Korn and Queen as well as dot matrices analyses we have compared the entire IL-2 gene and its 5' flanking sequences with those of ATL V (11,16). Four regions of limited homology with the viral LTR were noted, three of which were present in the 5' region of IL-2. These areas are depicted in Fig. 3. It is of interest to note that the homologous sequences shown in 3B occur at similar distances from the transcription initiation sites of the viral and IL-2 genes. For the virus this encompasses the cellular flanking sequence and 5' terminus of the LTR in one published sequence (11). Another published sequence of ATL V is



Figure 3. Homologies between ATLV and the IL-2 gene. Numbers without parentheses refer to the position relative to the first position in the published sequence. The numbers in parentheses give the relative position of the nucleotide to the transcription initiation site.

flanked by cellular sequences which have little or no homology to the IL-2 gene (16). The region of homology depicted in 3C extends from the TATA box up to the transcription initiation site for IL-2 and is associated with the R sequence, or terminal repeat sequence (16), within the LTR of ATLV. A fourth region of homology was noted within the second intron of the IL-2 gene and the R sequence of ATLV LTR.

Fugita et al. (9) noted two areas of the 5' sequence of the IL-2 gene which showed homology to the human gamma interferon gene sequence just 5' of the TATA box. We have found no other homologies within the additional 5' sequence of IL-2. Furthermore, the sequences of homology between IL-2 and human gamma interferon do not correspond to those regions of homology between IL-2 and ATLV.

The possible significance of the homologies between IL-2 and ATLV is at present unclear. However, since the expression of IL-2 and ATLV display specificity for T cells, it is possible that these regions are associated with the conferred specificity of expression.

ACKNOWLEDGMENTS

The authors are grateful to Dr. Jacob B. Maizel and John Owens for their help with analysis by dot matrix plots. N.J.H. was supported by a fellowship from the Leukemia Society of America and a grant from the Eli Lilly Research Laboratories.

REFERENCES

1. Morgan, D.A., Ruscetti, F.W. and Gallo, R.C. (1976) *Science* 193, 1007-1008
2. Robb, R.J. and Smith, K.A. (1981) *Mol. Immunol.* 18, 1087-1094
3. Robb, R.J., Munck, A. and Smith, K.A. (1981) *J. Exp. Med.* 154, 1455-1474
4. Smith, K.A. (1980) *Immunol. Rev.* 51, 337-357
5. Rosenberg, S.A., Grimm, E.A., McGrogan, M., Doyle, M., Kawasaki, E., Koths, K. and Mark, D.F. (1984) *Science* 223, 1412-1415
6. Gillis, S. and Watson, J. (1980) *J. Exp. Med.* 152, 1709-1719
7. Stobo, J.D., Wiskocil, R.L., Imboden, J.B., Kamen-Lewis, R.M. and Weiss, A. (1984) *Federation Proceedings* 43, 1734
8. Holbrook, N.J., Smith, K.A., Fornace, A.J., Comeau, C.M., Wiskocil, R.C. and Crabtree, G.R. (1984) *Proc. Natl. Acad. Sci. USA* 81, 1634-1638
9. Fujita, T., Takaoka, C., Matsui, H. and Taniguchi, T. (1983) *Proc. Natl. Acad. Sci. USA* 80, 7437-7441
10. Poiesz, B.J., Ruscetti, F.W., Gazdar, A.F., Bunn, P.A., Minna, J.D. and Gallo, R.C. 1980 *Proc. Natl. Acad. Sci. USA* 77, 7415-7419
11. Seiki, M., Hattori, S., Hirayama, Y. and Yoshida, M. (1983) *Proc. Natl. Acad. Sci. USA* 80, 3618-3622
12. Sanger, F., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl. Acad. Sci. USA* 74, 5463-5467
13. Queen, C.L. and Korn, L.J. (1980) *Methods Enzymol.* 65, 595-609
14. Maizel, J.V. and Lenk, R.P. (1981) *Proc. Natl. Acad. Sci. USA* 78, 7665-7669
15. Rubin, C.M., Houck, C.M., Deininger, P.L., Friedmann, T. and Schmid, C.W. (1980) *Nature* 284, 372-374
16. Seiki, M., Hattori, S. and Yoshida, M. (1982) *Proc. Natl. Acad. Sci. USA* 79, 6899-6902